drugset / Trial / NCT00092963

Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)

NCT00092963

Phase 3 Completed 529 enrolled Organon and Co
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to test the effectiveness of an approved drug in the early treatment of migraine while the pain is still mild.

Timeline

Start
2004-08-17
Primary completion
2005-01-14
Completion
2005-01-14

Drugs

EvaluationDrugModalityDoseRoute
Subject rizatriptan Unknown 10 mg

Indications